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OBJECTIVES: To evaluate use of resources and health-
related quality of life (HRQOL) in Spanish subjects with
IBS compatible symptoms meeting and not meeting the
Rome II criteria. METHODS: Cross-sectional study in a
representative sample of 222 subjects with IBS compati-
ble symptoms. Data were obtained in face-to-face inter-
views performed in the respondent’s home. Data on IBS
compatible symptoms, number of medical visits, diagnos-
tic tests, drugs, disability days, and restrictions on main
activity during the previous 12 months were compared
between subjects meeting the Rome II criteria and those who
did not. HRQoL was measured using the SF-36. RESULTS:
Compared to subjects with IBS compatible symptoms
who did not meet the Rome II criteria, a greater propor-
tion of subjects meeting the Rome II criteria had consulted
a health care professional (67.7 vs 41.4%), principally
general practitioners (49.2% vs 31.8%) and gastroenter-
ologists (27.7 vs 8.9%); underwent a diagnostic test (35.4%
vs 17.2%); were taking medication (70.8% vs 45.2%);
were unable to perform their main activity (21.5% vs 10.8);
or reported restrictions on their main activity (60% vs
27.4%). Subjects meeting IBS Rome II criteria reported
worse HRQOL than members of the general population
on all dimensions of the SF-36 (P  .05) except Physical
functioning and Role functioning. CONCLUSIONS: IBS
subjects meeting the Rome II criteria reported greater use
of health resources than subjects with IBS compatible
symptoms who did not meet the Rome II criteria, and
they reported worse HRQoL when compared with the
general population. 
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A multi-language Patient Assessment in upper Gastro-
intestinal disorders, the PAGI, has been developed for use
in international trials in patients with Gastroesophageal
Reflux Disease (GERD), dyspepsia and gastroparesis.
This comprehensive assessment is made of two comple-
mentary parts: a symptom questionnaire (PAGI-SYM),
and a Health Related Quality of Life questionnaire (PAGI-
QOL). OBJECTIVE: To assess the preliminary psycho-
metric properties of the PAGI-QOL in a US sample of
GERD patients. METHODS: 249 patients selected from
a previous epidemiological survey filled in the PAGI
questionnaire via phone interviews. Psychometric testing
included test of scaling assumptions, internal consistency,
test-retest reliability and clinical validity. RESULTS: The
seven hypothesized subscales of the 43-item PAGI-QOL
were confirmed by the item convergent validity (item-
scale correlation  0.40) for all but one item (0.39), and
by the item discriminant validity (scaling success from 94
to 100%) for all but one scale (67%). Excellent internal
consistency was observed with Cronbach’s alpha coeffi-
cient ranging from 0.76 to 0.95. Test-retest reliability in
subjects who were clinically stable over two weeks was
also excellent (intraclass correlation coefficient from 0.76
to 0.94). The PAGI-QOL significantly discriminated pa-
tients with different levels of symptom frequency and
symptom intensity, indicating its clinical validity. CON-
CLUSIONS: Preliminary psychometric results support
the reliability and the validity of the PAGI-QOL. An in-
ternational validation study is on going to establish the
structural cultural equivalence of the PAGI-QOL across
countries and its responsiveness.
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OBJECTIVES: Esomeprazole is a new proton pump in-
hibitor which has been shown to be superior to omepra-
zole in the healing of reflux oesophagitis. The objective
of this analysis was to compare the cost-effectiveness of
acute treatment for up to eight weeks with esomeprazole,
40 mg od, or omeprazole, 20 mg od, in patients with re-
flux oesophagitis. METHODS: Based on the results from
clinical studies, a simple decision analysis model was de-
signed to compare the cost-effectiveness of the two treat-
ment strategies. Patient management was based on re-
sults from a UK physician survey of patient management
in clinical practice. The UK survey results were adjusted
for Finland and Sweden based on expert opinions. Direct
medical costs in Finland, Sweden and the UK were used.
Time with Gastro-Oesophageal Reflux Disease (GORD),
defined as weeks with endoscopic lesions, was used as
the measure of effectiveness. RESULTS: The esomepra-
zole strategy was dominant over the omeprazole strategy.
Time with GORD was 2.9 weeks per patient in the es-
omeprazole strategy and 3.6 weeks in the omeprazole
strategy. The esomeprazole strategy incurred lower direct
medical costs than the omeprazole strategy. CONCLU-
SIONS: Esomeprazole is cost-effective compared with
omeprazole for the acute treatment of patients with re-
flux oesophagitis.
